Video

Dr. Helfand on how genomic testing provides real-time status of prostate tumor

Author(s):

Urology Times staff

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Expert on prostate cancer
Expert on prostate cancer
Expert on prostate cancer
Experts on prostate cancer
Around the Practice July 21, 2021: Bladder Cancer Cases
Genetic, Genomic Testing in Heavily Treated, Metastatic Castrate-Resistant Prostate Cancer
Genetic, Genomic Testing in Newly Diagnosed, High-Grade, High-Risk Prostate Cancer
Related Content
Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer
May 6th 2021

Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer

This article reviews new imaging technologies that may improve early detection of biochemical recurrence after definitive treatment for prostate cancer. This article also features insights from oncology experts Raoul Concepcion, MD; Judd Moul, MD; Brian Helfand, MD; Munir Ghesani, MD.
© 2025 MJH Life Sciences

All rights reserved.
OSZAR »